AnGes Inc - Company Profile
Powered by 
All the sales intelligence you need on AnGes Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AnGes Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AnGes Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
AnGes Inc (AnGes) is a biopharmaceutical company that discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. AnGes' lead product, Zokinvy, is used for the treatment of HGPS/PDPL. It has major projects under development, such as hepatocyte growth factor (HGF) gene therapy products for Chronic arterial occlusive disease, NF-κB decoy oligonucleotide for Chronic discogenic lumbar back pain, and the development of hypertension and COVID-19 DNA vaccines. The company also focuses on the development of rare diseases and has n-licensed drugs for Mucopolysaccharidosis Type VI and Hutchinson-Gilford Progeria Syndrome. It has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.
Headquarters
Japan
Address
Saito Bio-Incubator, 7-7-15, Saito-Asagi, Ibaraki, Osaka, 567-0085
Website
www.anges.co.jp
Telephone
81 072 6433590
No of Employees
56
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4563 (TYO)
Revenue (2024)
$5.6M
35.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
81.4%
(2024 vs 2023)
Market Cap*
$134.0M
Net Profit Margin (2024)
XYZ
86.3%
(2024 vs 2023)
* As of and is in US$
AnGes Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| HGPS/PDPL | Service: | Zokinvy |
| Pipeline: | Contract Testing Services | |
| HGF gene therapy product (Collategene) (AMG0001): Arteriosclerosis obliterans with lower limb ulcer | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, the company entered into an agreement with Stanford Medicine to create novel cancer therapies using genome editing technology. |
| 2024 | Contracts/Agreements | In July, the company signed an agreement with the Gunma Foundation for Health Promotion of AnGes Clinical Research Laboratory. |
| 2024 | Regulatory Approval | In May, Vasomune Therapeutics received fast track designation from the US Food and Drug Administration for AV-001 for the treatment of ARDS in patients hospitalized with viral and bacterial respiratory infections. |
Competitor Comparison
| Key Parameters | AnGes Inc | Takara Bio Inc | Kolon Life Science Inc | Kidswell Bio Corp | CG Invites Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | South Korea | Japan | South Korea |
| City | Ibaraki | Kusatsu | Seoul | Chuo-Ku | Seoul |
| State/Province | Osaka | Shiga | - | Tokyo | - |
| No. of Employees | 56 | 1,779 | 432 | 37 | 64 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ei Yamada, PhD | Chief Executive Officer; Director; President | Executive Board | 2002 | 76 |
| Yamada Hide | Director; President | Executive Board | 2024 | 76 |
| Norikazu Eiki | Director | Non Executive Board | 2014 | 78 |
| Makoto Hara | Director | Non Executive Board | 2024 | 75 |
| Naoya Sato | Director | Non Executive Board | 2024 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer